ntracerebral hemorrhage (ICH) is a devastating disease, which accounts for ≈10% to 15% of strokes with high mortality and morbidity.
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beneficial effects in ICH. In addition, many adverse events, including hypertension, macular edema, pulmonary toxicity, and hepatotoxicity, have been associated with fingolimod, because of its off-target interactions with other S1PR subtypes, particularly with S1PR3. [19] [20] [21] [22] Considering that disorders such as coronary artery disease are relatively common among ICH patients, 23 the clinical application of fingolimod in these patients is limited.
RPC1063 is a potent and selective S1PR1 modulator. RPC1063 has recently emerged as a new option for immune intervention. 24 Its efficacy and safety has been confirmed in relapsing remitting MS in phase III trials and inflammatory bowel disease in phase II trials. 25 Of interest, distinguished from fingolimod, RPC1063 has a reduced first-dose effect on heart rate with a dose-titration regimen and does not cause QTc prolongation, as demonstrated in a thorough clinical QT study. 20, [24] [25] [26] The profibrotic activity observed in heart and lung in patients treated with fingolimod was also not observed after RPC1063 treatment, suggesting its superior safety features versus fingolimod. 24 RP101075 is an active metabolite of RPC1063 with high potency and S1PR1 selectivity (>100-fold over S1PR5 and >10 000-fold over S1PR 2, 3, and 4). 27, 28 In addition, RP101075 has a high steady-state brain:blood ratio of 52. 26, 27 Because of these advantageous pharmacological features of RP101075, here we examined the effect of RP101075 on ICH in a mouse model.
Materials and Methods

Animals
Adult male C57BL/6J mice (7-8 weeks old) were obtained from Charles River Laboratories. Rag2 −/− mice (8-10 weeks old) were purchased from Taconic Biosciences, Inc. This study was conducted in accordance with the National Institutes of Health guidelines for the use of experimental animals. Experimental protocols were approved by the Tianjin Medical University General Hospital Animal Care and Use Committee. Adequate measures were taken to minimize the number of experiment animals used and to ensure minimal pain or discomfort in animals.
ICH Model
ICH was induced by a double-injection method described previously, 29 with minor modifications. Briefly, 30-μL nonheparinized blood was withdrawn from the angular vein after anesthesia and quickly transferred into a 50-μL syringe with a 26 G needle (Hamilton Company). Then mouse was fixed on a stereotactic frame (RWD Life Science). A 1-mm burr hole was drilled, and blood was infused at the caudate nucleus (2.3 mm lateral to midline, 0.5 mm anterior to bregma, and 3.5-mm depth below the surface of the skull). Each ICH model received 30-μL whole blood at a rate of 1 μL/min through the infusion pump (KD Scientific). During the process, needle was paused for 5 minutes before injection, then the first 5 μL was injected to generate a clotting along the needle track, after an additional 5-minute pause, the remaining 25 μL was injected during the following 25 minutes at the same rate of 1 μL/min. After completing the infusion, the needle was held in place for 20 minutes, and then it was slowly withdrawn at a rate of 1 mm/min over the course of 3 movements with 5-minute intervals. Finally, the burr hole was sealed with bone wax (Johnson & Johnson), sterilized and the wound was sutured. After surgery, animals were placed in a cage with free access to food and water. Warming lamps were used to provide thermal support throughout the procedure.
Study Design and Drug Administration
All animal experiments were designed, performed, and reported according to the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. 30, 31 Age-matched, male mice (C57BL/6J, 7-8 weeks; Charles River Laboratories, China) and Rag2 −/− mice (8-10 weeks old) were used in this study. All animals were housed in the animal care facility at Tianjin Medical University General Hospital (Tianjin, China) or Barrow Neurological Institute (Phoenix, AZ). This study was conducted in accordance with the local authorities, and the use of animals in research and all protocols was approved by the institutional animal care and use committee. All animal experiments to assess the efficacy of RP101075 were performed in both sites. ICH was induced by injection of autologous blood in 294 mice. Wild-type mice were randomly assigned into 3 groups: vehicle group (n=124), RP101075 group (n=124), and RP101075 plus W146, a S1PR1 antagonist, group (n=30). All animals received magnetic resonance imaging (MRI) tests for lesion location detection, and mice with lesions in the ipsilateral basal ganglia were included, whereas those with no lesions or with lesions only in the ventricles or deceased within 1 day were excluded. RP101075 was a gift from Receptos Inc., RP101075 was dissolved in 5% DMSO+5% Tween 20+90% 0.1 N HCl as the vehicle and stored at 4°C. The S1PR1 antagonist W146 was purchased from Tocris Bioscience and dissolved in 10% DMSO+25% Tween 20 in sterile water and stored at −20°C. To determine the therapeutic dosage and time window, mice were treated with either 0.3 or 0.6 mg/kg RP101075 at 30 minutes, 24 hours, or 72 hours after ICH induction, respectively, and 0.6 mg/kg RP101075 at 30 minutes after ICH was finally adopted. The 0.6 mg/kg RP101075, vehicle, or 0.6 mg/kg RP101075+10 mg/kg W146 were administered by oral gavage for 3 consecutive days starting from 30 minutes after ICH. For the S1PR1 targeting study, Rag2 −/− mice (n=16) that lack of T, B, and NKT cells (Barrow Neurological Institute) were used, with RP101075 administered using the same regimen and receiving the same measurements as wild-type mice. Data from groups of mice were collected and analyzed by at least 2 investigators who were blind to group assignment.
Neurological Function and Survival Evaluation
Neurological tests were performed at baseline, day 1, and day 3 after ICH induction. To comprehensively evaluate the motor, sensory, reflex, and balance functions, a battery of tests consisting of the modified Neurological Severity Score, Corner Turning test, and forelimb placing test were performed as previously described.
32,33 The 14-day survival index were evaluated between groups.
Magnetic Resonance Imaging
MRI detection for hematoma, lesion volume, and hemispheric edema was performed by serial MRI on a 7.0 T Siemens ClinScan scanner at day 1 and day 3 after ICH. Susceptibility-weighted images (repetition time, 21.0 ms; echo time, 8.0 ms; 17 slices; 0.3-mm thickness) were acquired to determine hematoma volume and T2-weighted images (turbo RARE pulse sequence, echo time 41.0 ms, repetition time, 3380.0 ms; 16 slices; 0.5-mm thickness) were acquired to detect lesion volume and hemispheric volume. The volumes were manually outlined and calculated by multiplying the sum of the volume by the distance between sections (0.3 mm in susceptibility-weighted images and 0.5 mm in T2-weighted images) using MIPAV software. Brain edema (%) was expressed as ([ipsilateral hemisphere volume−contralateral hemisphere volume]/contralateral hemisphere volume)×100%.
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Brain Water Content Assessment
At days 1 and 3 after surgery, brains were removed for brain water content measurement as described in the online-only Data Supplement.
Hemoglobin Quantification
At days 1 and 3 after surgery, brains tissues were homogenized for hemoglobin measurement as described in the online-only Data Supplement.
Isolation of Cellular Components From Central Nervous System and Peripheral Blood for Flow Cytometry Analysis
Brain tissues and venous blood at day 1 and day 3 after surgery were collected for flow cytometry analysis to detect microglia 
ELISA
Ipsilateral hemisphere tissues and serum were collected at day 1 and day 3 for ELISA detection for interleukin-1β and tumor necrosis factor-α as described in the online-only Data Supplement.
Assessment of Blood-Brain Barrier Permeability
At day 3 after surgery, Evans Blue extravasation was quantified for detecting blood-brain barrier permeability as described in the onlineonly Data Supplement.
Western Blot Analysis for Tight Junctions
At day 3 after ICH, ipsilateral hemispheres were homogenized for detecting expression of tight junctions using Western blot as described in the online-only Data Supplement.
Analysis of Neuronal Apoptosis
Three days after ICH, the extent of cell death was assessed and quantified by TdT-mediated Biotin-dUTP Nick End labeling (TUNEL) stain using a TUNEL kit (Roche) as described in the online-only Data Supplement.
Statistical Analysis
All data were expressed as mean±SEM and analyzed by SPSS 18.0 software. Statistical differences were measured by unpaired 2-tailed Student t test for comparison of 2 groups or ANOVA followed by Bonferroni post hoc test for multiple comparisons. The survival index was analyzed by Gehan-Breslow Wilcoxon test, and P<0.05 was considered statistically significant.
Results
RP101075 Attenuated Neurodeficits and Increased Survival After ICH
To comprehensively determine the impact of RP101075 on ICH, modified Neurological Severity Score, corner turning, and forelimb placing tests were performed to evaluate motor, sensory, reflex, and balance functions, respectively. RP101075 significantly attenuated clinical severity in all three tests ( Figure 1A-1C ) and improved survival after ICH ( Figure 1D) . A selective S1PR1 antagonist, W146, blocks the effects of RP101075 on the neurological outcomes and survival index after ICH ( Figure 1A-1D ). These data indicate that modulation of S1PR1 using RP101075 is sufficient to improve neurological outcomes and survival after ICH.
RP101075 Ameliorated Brain Edema After ICH
MRI showed significant midline shift and brain edema at day 1 and 3 after ICH (Figure 2A ). When compared with the vehicle-treated group, RP101075 reduced lesion volume, brain edema, and midline shift at day 1 and 3 in MRI (Figure 2A and 2B). Furthermore, measurements of brain water content showed a significant decrease in the ipsilateral hemisphere at day 1 and 3, as well as in the contralateral hemisphere at day 3, in the RP101075 group when compared with the vehicle-or W146+RP101075-treated groups ( Figure 2C ; Figure I in the online-only Data Supplement). In addition, hematoma volume shown in susceptibility-weighted images and hemoglobin level were not significantly different across these groups ( Figure 2B and 2C). These data suggest that RP101075 mainly has an impact on brain edema but not on hematoma.
Impact of RP101075 on Inflammatory Response After ICH
Next, we sought to understand how RP101075 affects brain edema after ICH. Figure 3 ). In addition, RP101075 reduced levels of interleukin-1β and tumor necrosis factor-α Figure 2 . RP101075 ameliorated brain edema with similar hematoma volume. At days 1 and 3 after intracerebral hemorrhage (ICH), sequential 7T magnetic resonance imaging (MRI) and brain water content assessments were performed to evaluate hematoma, lesion volume, and brain edema. T2-weighted image (T2WI) sequences were scanned to assess lesion volume and brain edema. Susceptibility-weighted image (SWI) sequences were scanned to detect the size of hematoma. A, RP101075 reduced brain edema, as well as alleviated lesion volume and midline shift at days 1 and 3 after ICH. The hematoma volume was not significantly altered after RP101075 treatment. B, RP101075 reduced brain edema and lesion volume seen in T2WI images at days 1 and 3 after ICH, without notable effects on hematoma volume. C, RP101075 decreased brain water content in ipsilateral hemisphere at days 1 and 3 and in contralateral hemisphere at day 3 after ICH without obvious change in hemoglobin volume between groups. Data were presented as mean±SEM, *P<0.05, **P<0.01 compared with vehicle group, #P<0.05, ##P<0.01, compared with RP101075+W146 group, n=7 per group for magnetic resonance imaging; n=40 in vehicle or RP101075 group and n=20 in RP101075+W146 group for assessment of brain water content; n=24 per group for hemoglobin detection. 
Impact of RP101075 on BloodBrain Barrier Permeability
To determine the impact of RP101075 on neurovascular function in ICH, we examined blood-brain barrier (BBB) permeability and the integrity of tight junctions after RP101075 treatment. RP101075 significantly reduced Evans Blue extravasation at day 3 after ICH ( Figure 4A and 4B), suggesting a decrease in BBB permeability after RP101075 treatment. Significantly increased expression of occludin and zonula occludens-1 was seen in ICH mice after receiving RP101075 when compared with vehicle-treated controls ( Figure 4C and 4D ). An increase of claudin-5 expression was also noticed but was not statistically significant ( Figure 4C and 4D).
Impact of RP101075 on Neuronal Death After ICH
Three days after ICH, brain sections from ICH mice receiving RP101075 or vehicle controls were stained with TUNEL to determine cell death. Quantitation of TUNEL + cells in the perihematomal area suggests reduced cell apoptosis after RP101075 treatment ( Figure 5 ).
Discussion
Here, we demonstrate that RP101075 treatment attenuated neurological deficits, and brain edema in a mouse model of ICH. RP101075 can reduce brain-infiltrating immune cells, enhance BBB integrity, and attenuate cell death after ICH. A S1PR1 antagonist W146 diminished the neuroprotective effects of RP101075. Our results suggest that selective S1PR1 modulation using a novel compound RP101075 is sufficient to attenuate brain inflammation and provide protection after ICH.
Neurodeficits and brain edema are 2 surrogate markers for clinical evaluation of ICH. In this study, we chose to use an autologous blood infusion model because of its ability to mimic the rapidly developing bleeding without actually rupturing vessels or using exogenous factors. 5, 7 Thirty microliters of blood infused in mice reflects a 60-mL intracerebral hematoma in humans 29 and provides a reproducible brain edema size during hematoma evolution. These advantages suggest autologous blood infusion model as a suitable model for this study.
Recently, fingolimod as a S1PR modulator was shown to be effective at reducing brain injury after ICH in rodents and in patients. [13] [14] [15] [16] [17] [18] Thereafter, increasing attention has been focused on S1PR modulation as a potential immune intervention approach for ICH. 11, [35] [36] [37] However, several limitations of fingolimod may preclude its clinical applications. First, the diverse subtypes of S1PR expressed on peripheral immune cells and brain-intrinsic cells preclude a better understanding of the cell types and compartments responsible for the mechanisms of action of fingolimod. Of note, despite the pivotal role of S1PR1 in the mediation of fingolimod's effects, it remains unclear whether S1PR1 modulation is sufficient and necessary for fingolimod to provide beneficial effects. In addition, the optimal timing for immune interventions using S1PR modulators is still undefined in ICH. Last but not the least, the activation of S1PR3 by fingolimod was at least partially responsible for its side effects on the cardiovascular system and organ fibrosis, which may cause prominent safety issues. [19] [20] [21] [22] RP101075 is S1PR1 selective and has extremely low affinity to other subtypes of S1PRs such as S1PR3. 27 The clinical pharmacokinetic properties of RP101075 are characterized by a Tmax of ≈7 hours and a half-life of 19 hours. 27 The toxicology data also suggest that the dose of 0.6 mg/kg is safe in preclinical studies. [24] [25] [26] [27] The efficacy of RP101075 has been tested in experimental allergic encephalomyelitis mice and compared with FTY720. 27 Dose of 0.6 mg/kg RP101075 can cause ≈60% reduction in the counts of circulating lymphocytes, which resembles 1-mg/kg FTY720. 27 In addition, we show that 0.6 mg/kg of RP101075 can produce sufficient efficacy of protection, in comparison with 0.3-mg/kg RP101075 or 1-mg/kg FTY720 ( Figure I in the online-only Data Supplement). In terms of the potency, selectivity, and dose-effect relation of RP101075, we therefore chose the dose of 0.6 mg/kg in the current study.
We showed that RP101075, a selective S1PR1 modulator, improves neurological outcomes and attenuates brain edema after ICH. Of note, the beneficial effect of RP101075 on neurological outcomes and brain edema was blocked by W146, a selective RP101075 antagonist. [38] [39] [40] Together with the reduced cellular infiltration and inflammatory cytokine expression after RP101075 treatment, these results support the notion that modulation of S1PR1 is sufficient to suppress brain inflammation and provide protection in ICH. The superior pharmacological features along with its efficacy may qualify RP101075 as a promising candidate for future ICH investigations. Our findings cannot conclude that modulation of S1PR1 on immune cells is the sole mechanism responsible for the protection offered by RP101075. Considering the wide distribution of S1PR1 on a variety of cells involved in the process of ICH and the preferential distribution of RP101075 in the brain, other potential cellular targets beyond immune cells and their relevant anatomic locations for immune interventions await further investigations. It is noteworthy that our results are consistent with previous findings that early immune interventions are beneficial in acute ICH. 7 However, the current study does not provide sufficient information on the optimal time window for S1PR1 modulation to achieve maximal beneficial effects after ICH. Because of its importance for the design of immunomodulatory therapies, this information is critical and should be examined in future studies. The decreased TUNEL + cells after RP101075 treatment also suggests the possibility of direct protection of neuronal cells by S1PR1 modulation ( Figure 5 ; Figure III in the online-only Data Supplement), which is consistent with previous studies using S1PR modulators in stroke models. 14, 17, 41 In addition, the similar efficacies of RP101075 and FTY720 suggest that the beneficial effect of FTY720 in ICH may be largely mediated by its impact on S1PR1 ( Figure I in the online-only Data Supplement). This finding is consistent with previous reports that the benefit of FTY720 requires S1PR1 in animal models of ischemic stroke and MS. 41, 42 Of interest, one recent report suggests the benefit of FTY720 in experimental ischemic stroke depends on lymphocytes because of the prothrombotic impact of lymphocytes on microperfusion. 16 Another report shows that the benefit of FTY720 in a mouse model of MS depends on its action on astrocytes. 41 In addition to these findings, we found that although to a lesser extent, RP101075 can still reduce neurodeficits and brain edema in Rag2 −/− mice ( Figure IV in the online-only Data Supplement). These results suggest that the protection of RP101075 may not entirely depend on peripheral lymphocytes including T, B, and NKT cells. Nevertheless, given the widespread expression of S1PR1 on multiple types of cells, the operating mechanisms of RP101075 in ICH require future investigation.
In conclusion, we demonstrate that selective S1PR1 modulation is sufficient to provide protections after ICH. The benefit of selective S1PR1 modulation using RP101075 may involve its suppression of inflammatory responses, enhancement of BBB integrity, and reduction of cell death after ICH. The superior pharmacological features of RP101075 along with its potency to reduce brain damage after ICH suggest that S1PR1 modulation may serve as a viable approach for future investigations of ICH therapy.
Supplemental Methods
1
Brain water content assessment 2 At days 1 and 3 after surgery, brains were removed and divided into three parts: left hemisphere, right hemisphere 3 and cerebellum. Tissues were quickly weighed on an electronic analytical balance to obtain wet weight. Then the 4 tissues were dried for 24 hrs at 100 °C to obtain dry weight. The formula for calculation was as follows: [(Wet 5 Weight-Dry Weight) / Wet Weight] x 100%. 6 7 Hemoglobin quantification 8 We also detected the amount of extravasated blood in the brain tissue by performing hemoglobin ELISA using a 9 commercial kit (Kamiya Biomedical Company, USA) and a microplate photometer (Thermo Scientific, Varioskan 10 Flash, USA) capable of reading at 450 nm and 570 nm were used to calculate quantity of hemoglobin. 11 12 Isolation of cellular components from CNS and peripheral blood for flow cytometry analysis 13 Brain tissues were mechanically homogenized through a 40 μm nylon cell strainer (Becton Dickinson, Franklin Lakes, 14 NJ, USA) in PBS on ice, then cell suspension was collected and centrifuged at 400 x g for 10 min; the pellet was 15 resuspended in 5 ml of 60 % Percoll (GE Healthcare Bio Science AB, Uppsala, Sweden) and 5 ml 30 % Percoll was 16 overlaid on the top of the 60 % solution. The gradient was then centrifuged at 500 × g for 20 min and cells were 17 collected on the interface between 30 % and 60 % Percoll. Isolated cells were washed once (1500 x rpm, 8 min) in 18 15 ml PBS and were resuspended in 1 % bovine serum albumin (BSA) for staining. Venous blood (500 μl per mouse) 19 was simultaneously collected and lymphocytes were isolated according to the manufacturer's instructions for the 20 Ficoll gradient media (GE Healthcare Bio Science AB, Uppsala, Sweden) and RBC lysis buffer (GE Healthcare Bio 21 Science AB, Uppsala, Sweden). Flow cytometry staining buffer (100 μl) was added to re-suspend the isolated cells 22 for flow cytometry analysis. Cells isolated from the either the CNS or venous blood were diluted to 1 x 10 6 /ml and 23 stained for anti-CD45 FITC (Cat#103107, Biolegend), anti-CD4 PE (Cat#100407, Biolegend), anti-CD8 APC 24 (Cat#100711, Biolegend), anti-NK1.1 PE-Cy5 (Cat#108715, Biolegend), anti-CD19 PerCP (Cat#115531, Biolegend), 25 anti-Gr-1 PE-Cy7 (Cat#108415, Biolegend) and anti-CD11b APC-Cy7 (Cat#101225, Biolegend), and isotype control 26 respectively. Flow cytometry was performed using a FACS Calibur (Aria III, BD Bioscience) and data were analyzed 27 by Flow Jo software (Tree Star, US). 28 29 Enzyme-linked immunosorbent assay (ELISA) 30 Ipsilateral hemisphere tissues (~100 mg) were homogenized and supernatants were collected after centrifugation. 31 Supernatants from brain homogenates and blood serum samples were used to analyze the expression of IL-1β and 32 TNF-α using a commercial ELISA kit (Biolegend, USA) and a microplate photometer (Thermo Scientific, Varioskan 33 Flash, USA) capable of reading at 450 nm and 570 nm. 34 35 Assessment of blood-brain barrier permeability 36 Evans Blue dye (Sigma, USA) was used as a tracer to measure the BBB permeability at day 3 as previously 37 described. 1 2 % Evans blue (2 ml/kg) was injected intravenously 2 h prior to sacrifice. The ipsilateral hemisphere 38 was weighed on an electronic balance (with an accuracy of 0.1 mg) and homogenized into a test tube with 5 ml of 39 formamide (Sigma, USA), then incubated in a 60 °C water bath for 72 h. After centrifugation at 1000 x rpm for 40 5 min, the supernatants were collected for testing. A microplate reader (Thermo Scientific, Varioskan Flash, USA) 41 was used (λ = 450, 570 nm) to measure the OD of the supernatant and the standards (80, 40, 20, 10, 5, 2.5, 1.25, 42 0.625, 0.3125, 0.15625 μg /ml). The concentration of EB was calculated by the formula as follows: EB content in 43 brain tissue (μg /g wet brain) = EB concentration x formamide (ml)/wet weight (g). 92 ICH mice were treated with vehicle, 0.3 or 0.6 mg/kg RP101075, or 1 mg/kg FTY720 at 30 min, 24h or 72h after 93 injection of autologous blood. RP101075 0.6 mg/kg at 30 min after ICH reduced neurodeficits and brain edema at 94 day 1 and 3 after ICH which resembled the FTY720 1 mg/kg at 30min. Data are expressed as mean ± SEM. **p < 95 0.01, versus vehicle group. n = 20 per group for the evaluation of mNSS, n = 40 per group for the assessment of 96 brain edema. 97
